Diminished vascular endothelial function results in a decreased vasodilator capacity and is associated with erectile dysfunction (ED) in patients afflicted with type 2 diabetes.
The current study was designed to evaluate whether daily use of sildenafil could alter endothelial function and improve penile rigidity in a group of diabetic ED patients.
A double-blind, placebo-controlled, prospective trial was conducted with 24 type 2 diabetic men who were randomized into two groups: one receiving daily sildenafil (Viagra, 50 mg, n = 12) and the other placebo (n = 12) for 10 weeks.
Erectile function was captured subjectively using the international index of erectile function (IIEF-5) and endothelial function was objectively monitored via brachial artery flow mediated dilation (FMD).
Amongst the placebo and sildenafil groups there were no significant differences in average patient age, time from type 2 diabetes diagnosis, duration of ED or baseline IIEF-5 scores. Past medical histories, in the form of smoking, alcohol consumption, hypertension and hyperlipidemia were also similar. At the conclusion of the 10 week trial, patients who received daily sildenafil had significantly improved erectile rigidity as captured by IIEF-5 (p < 0.001) and increased endothelial function via brachial artery FMD (p < 0.01).
Endothelial function in type 2 diabetic men is enhanced with daily sildenafil. Improved erectile rigidity and enhanced vascular circulation can be noted after 10 weeks of daily sildenafil use.
Written by:
Deyoung L, Chung E, Kovac JR, Romano W, Brock GB. Are you the author?
Reference: J Androl. 2011 Jun 16. Epub ahead of print.
doi: 10.2164/jandrol.111.013367
PubMed Abstract
PMID: 21680809
UroToday.com Erectile Dysfunction (ED) Section
